emtricitabinerilpivirinetenofovir trade names complera eviplera fixeddose combination antiretroviral drugs treatment drug codeveloped gilead sciences johnson johnsons tibotec division approved food drug administration august european medicines agency november patients previously treated available onceaday single tablet european union marketed eviplera us emtricitabinerilpivirinetenofovir indicated treatment adults na√Øve medications virus developed resistance antihiv medications copies per ml rna blood viral load contraindications use emtricitabinerilpivirinetenofovir following medicines contraindicated lead reduced blood levels rilpivirine turn reduce effectiveness httpsenwikipediaorgwikiemtricitabinerilpivirinetenofovir